HRTS
Obesity & Cardiometabolic ETF
Invest in the weight-loss drug revolution and beyond
Why HRTS ETF?
Underpenetrated, large market
Obesity is forecast to affect one in four
people globally by 2035, and obesity-
related conditions like diabetes and
heart disease represent vast markets
with significant growth potential.
Source: World Obesity Atlas, March 2023
Innovation
The Industry is witnessing significant
progress in obesity therapeutics led by
new drugs such as Ozempic and
Wegovy, as well as a renaissance in
cardiovascular therapies through novel
platforms like gene editing.
Research expertise
The fund conducts deep and
comprehensive research, in an effort to
identify those companies that deliver
breakthrough solutions at attractive
valuations.
Barriers to entry
In our view, many of the businesses
identified have high barriers to entry,
such as costly and lengthy clinical trials,
large salesforce requirements in primary
care markets, and substantial patent
protection.
Uncorrelated
Performance of many companies relies
on clinical or commercial success, which
is an uncorrelated source of return.
Fund Overview
Fund Details
As of April 26, 2024
Fund Summary
The actively managed Tema Obesity & Cardiometabolic ETF seeks to provide long-term growth of capital by investing in companies leading the fight against obesity and cardiometabolic diseases. Obesity is on the cusp of a revolution in therapeutics, while heart disease, the most common cause of death, is witnessing a renaissance of therapies driven by genetic insights and tools. The complex combination of scientific, regulatory and financing risks requires investment and scientific expertise to navigate this secular theme.
Source: Our World in Data, November 2023.
Portfolio Manager
Investment Partner
David K. Song, MD, PhD, CFA
How does the Tema HRTS ETF fit in a portfolio?
Investment Style Box
Source: Tema. The investment style Box reveal’s a fund’s investment strategy by showing its investment style and market capitalization based on the fund’s portfolio holdings.
Potential Portfolio
Equity Allocation
3-5%
Equity Satellite
HRTS ETF
Equity core
Where could a position be funded from?
- Could be a more targeted alternative to existing healthcare or biopharma exposure in a portfolio.
- Provides a balanced exposure across key technologies and company risk profiles.
- Could replace a satellite or a growth-oriented position.
Portfolio Breakdown
Top 10 holdings
As of April 26, 2024
Country Breakdown
United States
76.88%Denmark
10.05%United Kingdom
3.05%Ireland
2.89%Others
7.13%Industry Breakdown
Healthcare
98.24%Cash & Cash Equivalents
1.79%- Performance
- Distributions
- Premium / Discount
Prices & Performance
- Mar 31, 2024
- Mar 31, 2024
HRTS
3 months
1 Year
3 Years
5 Years
Since inception
Performance data quoted represents past performance and is no guarantee of future results. Investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Current performance may be lower or higher than the performance data quoted. Returns for periods of less than one year are not annualized.
The market price returns are based on the official closing price of an ETF share or, if the official closing price isn’t available, the midpoint between the national best bid and national best offer (“NBBO”) as of the time the ETF calculates current NAV per share, and do not represent the returns you would receive if you traded shares at other times. NAVs are calculated using prices as of 4:00 PM Eastern Time. The first trading date is typically several days after the fund inception date. Therefore, NAV is used to calculate market returns prior to the first trade date because there is no bid/ask spread until the fund starts trading.
Distributions
Record Date
Ex-Date
Payable Date
Total Distribution
Income
ST Cap Gains
Premium/Discount
Days Traded at Nav
Days Traded at Premium
Days Traded at Discount
HRTS NAV / Market Price
Risk Information
Carefully consider the Fund’s investment objectives, risk factors, charges and expenses before investing. This and additional information can be found in the Fund’s prospectus or summary prospectus, which may be obtained by visiting www.temaetfs.com.
Read the prospectus carefully before investing.
On 03/25/2024 the Tema Cardiovascular and Metabolic ETF was renamed Tema Obesity & Cardiometabolic ETF. Investing involves risk including possible loss of principal. There is no guarantee the adviser’s investment strategy will be successful.
Industry Concentration Risk: Because the Fund's assets will be concentrated in an industry or group of industries, the Fund is subject to loss due to adverse occurrences that may affect that industry or group of industries.
Biotechnology Industry Risk: The biotechnology industry can be significantly affected by patent considerations, including the termination of patent protections for products, intense competition both domestically and internationally, rapid technological change and obsolescence, government regulation and expensive insurance costs due to the risk of product liability lawsuits. In addition, the biotechnology industry is an emerging growth industry, and therefore biotechnology companies may be thinly capitalized and more volatile than companies with greater capitalizations.
Sector Focus Risk: Obesity and Cardiology companies are highly dependent on the development, procurement and marketing of drugs and the protection and exploitation of intellectual property rights. A company’s valuation can also be greatly affected if one of its products is proven or alleged to be unsafe, ineffective or unprofitable. The stock prices of Obesity and Cardiology companies have been and will likely continue to be very volatile. The costs associated with developing new drugs can be significant, and the results are unpredictable.
Newly developed drugs may be susceptible to product obsolescence due to intense competition from new products and less costly generic products. Moreover, the process for obtaining regulatory approval by the U.S. Food and Drug Administration or other governmental regulatory authorities is long and costly and there can be no assurance that the necessary approvals will be obtained or maintained. Companies in the medical equipment industry group may be affected by the expiration of patents, litigation based on product liability, industry competition, product obsolescence and regulatory approvals, among other factors.
Investing in foreign and emerging markets involves risks relating to political, economic, or regulatory conditions not associated with investments in U.S. securities and instruments. In addition, the fund is exposed to currency risk.
Because the Funds evaluate ESG factors to assess and exclude certain investments for non-financial reasons, the Funds may forego some market opportunities available to funds that do not use these ESG factors.
Tema Global Limited serves as the investment adviser to Tema Obesity & Cardiometabolic ETF (the “Fund”), and NEOS Investments, LLC serves as a sub adviser to the Fund. The Fund is distributed by Foreside Fund Services LLC, which is not affiliated with Tema Global Limited nor NEOS Investments, LLC. Check the background of Foreside on FINRA’s BrokerCheck.